Similarly, in a phase I trial of nivolumab in 90 patients with unresectable melanoma, overall response rates were observed in 67% of patients with PD-L1-positive tumors (≥5%) as compared to 19% of patients with PD-L1-negative tumors [9]. Here, CD274 is linked to melanoma.